CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04082364
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:42.680979+00:00
- Published At
- 2025-04-22T00:00:00+00:00
- Record Updated At
- 2025-06-08
- Results Posted At
- 2025-04-22
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Gastric Cancer", "Gastroesophageal Junction Cancer", "HER2-positive Gastric Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-08"- protocolSection.identificationModule.nctId
"NCT04082364"- protocolSection.identificationModule.officialTitle
"A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-na\u00efve, HER2-Positive Gastric or Gastroesophageal Junction Cancer"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2", "PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-04-22"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.